Daily Signals
2496 companies scored · 2026-10-14 run in progress: 850 of ~5379 signals so far · Total · absolute moveSwitch to Alpha · 30D 90D
Distribution of the day's forecasts
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
289 companies
Sorted by market cap ↓ · forecast rankings are part of the paid plans
| Ticker | Rating | 90D | Δ | |
|---|---|---|---|---|
| LLYELI LILLY & Co | +2.65% | · | ||
| JNJJOHNSON & JOHNSON | Unlock rating and forecasts | |||
| ONCBeOne Medicines Ltd. | +2.94% | · | ||
| MRKMerck & Co., Inc. | Unlock rating and forecasts | |||
| AMGNAMGEN INC | Unlock rating and forecasts | |||
| GSKGSK plc | Unlock rating and forecasts | |||
| GILDGILEAD SCIENCES, INC. | +2.61% | · | ||
| PFEPFIZER INC | +3.11% | · | ||
| MRNAModerna, Inc. | Unlock rating and forecasts | |||
| ARGXARGENX SE | Unlock rating and forecasts | |||
| TEVATEVA PHARMACEUTICAL INDUSTRIES LTD | +2.73% | · | ||
| RVMDRevolution Medicines, Inc. | Unlock rating and forecasts | |||
| IDXXIDEXX LABORATORIES INC /DE | Unlock rating and forecasts | |||
| BIIBBIOGEN INC. | Unlock rating and forecasts | |||
| RPRXRoyalty Pharma plc | +2.96% | · | ||
| ZTSZoetis Inc. | Unlock rating and forecasts | |||
| ALNYALNYLAM PHARMACEUTICALS, INC. | Unlock rating and forecasts | |||
| ZLABZai Lab Ltd | +2.19% | ▲ 1 | ||
| ROIVRoivant Sciences Ltd. | +3.26% | · | ||
| UTHRUNITED THERAPEUTICS Corp | Unlock rating and forecasts | |||
| BNTXBioNTech SE | +2.66% | · | ||
| INSMINSMED Inc | Unlock rating and forecasts | |||
| VTRSViatris Inc | +2.50% | · | ||
| EXELEXELIXIS, INC. | Unlock rating and forecasts | |||
| NBIXNEUROCRINE BIOSCIENCES INC | Unlock rating and forecasts | |||
| SMMTSummit Therapeutics Inc. | +3.06% | · | ||
| JAZZJazz Pharmaceuticals plc | Unlock rating and forecasts | |||
| CORTCORCEPT THERAPEUTICS INC | Unlock rating and forecasts | |||
| HALOHALOZYME THERAPEUTICS, INC. | +3.21% | · | ||
| TECHBIO-TECHNE Corp | Unlock rating and forecasts | |||
| ELANElanco Animal Health Inc | Unlock rating and forecasts | |||
| BMRNBIOMARIN PHARMACEUTICAL INC | Unlock rating and forecasts | |||
| RGENREPLIGEN CORP | Unlock rating and forecasts | |||
| TWSTTwist Bioscience Corp | Unlock rating and forecasts | |||
| KRYSKrystal Biotech, Inc. | +3.14% | · | ||
| CYTKCYTOKINETICS INC | +2.80% | · | ||
| ARWRARROWHEAD PHARMACEUTICALS, INC. | Unlock rating and forecasts | |||
| AXSMAxsome Therapeutics, Inc. | Unlock rating and forecasts | |||
| SYRESpyre Therapeutics, Inc. | Unlock rating and forecasts | |||
| IONSIONIS PHARMACEUTICALS INC | +2.57% | · | ||
| PRAXPraxis Precision Medicines, Inc. | Unlock rating and forecasts | |||
| ABVXAbivax S.A. | Unlock rating and forecasts | |||
| ALKSAlkermes plc. | +2.92% | · | ||
| IOVAIOVANCE BIOTHERAPEUTICS, INC. | Unlock rating and forecasts | |||
| LNTHLantheus Holdings, Inc. | Unlock rating and forecasts | |||
| AMRXAmneal Pharmaceuticals, Inc. | +2.97% | · | ||
| IMVTImmunovant, Inc. | Unlock rating and forecasts | |||
| KODKodiak Sciences Inc. | Unlock rating and forecasts | |||
| BLRXBioLineRx Ltd. | +2.15% | · | ||
| PTCTPTC THERAPEUTICS, INC. | +2.91% | · | ||
By sector
Median 90D forecast per sector. Click to filter.
Rating changes
Unlock the full ranking
Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.
See plans Create a free accountRatings are relative: the forecasts of the latest complete daily run (2026-10-13) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.